Hologic has announced it has finalised the acquisition of Mobidiag, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation. The acquisition of Mobidiag will extend its portfolio into the large, fast growing acute care segment, broadening our instrument portfolio and testing capabilities worldwide. It will also strengthen Hologic’s global footprint and accelerate regional time-to-market. In addition, the acquisition will extend Hologic’s research and development capabilities in Europe with Mobidiag’s expertise complementing that of its other research and development facilities.
“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, Hologic’s group president, international. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”
Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management,and healthcare associated infections (HAIs). Its Amplidiag and Novodiag testing platforms deliver results in 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians.